# JUDGE — L4-TICK31-iter1

**Loop:** L4-TICK31 · **File:** `src/content/comparisons/retatrutide-vs-semaglutide.mdx`
**Judge:** independent (did not write the increment) · **Date:** 2026-09-02
**Implementer note:** `.planning/seo-engine/runs/2026-09-01/TICK31.md`

## Verdict: KEEP

## Independent fetches (commands actually run, 2026-09-02)

All raw responses saved under `.planning/seo-engine/runs/2026-09-01/judge/`.

```
curl.exe -s "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=<PMID>&rettype=abstract&retmode=text"
  → _fetch-37366315.txt, _fetch-33567185.txt, _fetch-37952131.txt, _fetch-41090431.txt,
    _fetch-33625476.txt, _fetch-36216945.txt   (all HTTP 200, exit 0)
curl.exe -s "https://clinicaltrials.gov/api/v2/studies/<NCT>"   (full records)
  → _full-nct05929066.json, _full-nct05929079.json, _full-nct05882045.json,
    _full-nct05931367.json, _full-nct06383390.json
curl.exe openFDA drugsfda generic_name:"retatrutide" → HTTP 404
curl.exe openFDA drugsfda application_number:"NDA209637" → brand_name "OZEMPIC"
rg -n -i "census|28\.7|MACE|17\.5|24\.2|..." src/content/comparisons/retatrutide-vs-semaglutide.mdx
Test-Path src/content/peptides/retatrutide.mdx → True ; semaglutide.mdx → True
```

## Fail-condition checklist (from dispatch)

| # | Must-fail condition | Result | Evidence |
|---|---|---|---|
| 1 | TRIUMPH 28.7% as a result | **PASS** — absent | `rg "28\.7"` zero hits. Page: "The design paper reports **no efficacy percent**" (line 176). |
| 2 | −17.5% attributed to 4 mg at 48 weeks | **PASS** — corrected | Line 154: "−17.5% is 12 mg at **24 weeks**, not 4 mg at 48 weeks." Abstract confirms: −17.5% = 12-mg group at 24 wk (primary). |
| 3 | Census FAQ | **PASS** — numbers gone | No "43/40", "67/52" anywhere. One disavowal sentence survives ("does not quote a live source census", line 28) — see LOW-1. |
| 4 | SELECT 20% MACE headline | **PASS** | Line 190: HR 0.80 (0.72–0.90), 569/8803 (6.5%) vs 701/8801 (8.0%). No "20%" string on page. |
| 5 | Unresolved PMIDs/NCTs | **PASS** | All 6 PMIDs efetch 200 + title topical-match (below). All 6 NCTs fetched live from CT.gov v2. |
| 6 | Trailing-slash compare links | **PASS** | Only `/peptides/retatrutide` and `/peptides/semaglutide`, no trailing slash; both slugs exist on disk. |
| 7 | Dosing / purchasing / medical advice | **PASS** | Trial-arm doses reported as evidence, no regimen advice, no sourcing language; educational disclaimer present (line 238). |
| 8 | Implementer stamped own KEEP | **PASS** | TICK31.md header: "implementer note (not a KEEP)"; "Did not mark KEEP." |

## L4 criteria (LOOPS.md) — per-criterion

**Estimands — PASS.**
- Retatrutide P2 (PMID 37366315): page labels 24 wk **primary** / 48 wk **secondary** and states "The abstract does not name a treatment-regimen estimand." Fetched abstract confirms: primary = % change at 24 wk; no estimand language. Table values identical to abstract: 24 wk −7.2/−12.9/−17.3/−17.5 vs −1.6; 48 wk −8.7/−17.1/−22.8/−24.2 vs −2.1; responders 92/75/60, 100/91/75, 100/93/83, 27/9/2. HR-increase peak at 24 wk confirmed.
- STEP 1 (PMID 33567185): page names **treatment-regimen**; abstract: "assessed effects regardless of treatment discontinuation or rescue interventions." −14.9% vs −2.4%, ETD −12.4 (95% CI −13.4 to −11.5, P<0.001), 86.4/69.1/50.5 vs 31.5/12.0/4.9, −15.3 vs −2.6 kg, GI d/c 4.5% vs 0.8% — all identical.
- STEP 3 (PMID 33625476): −16.0% vs −5.7% (−10.3 pp), 86.6% vs 47.6%, GI 82.8% vs 63.2%, d/c 3.4% vs 0% — identical. Page's "abstract does not name a treatment-regimen estimand" confirmed (no estimand/regardless in abstract). IBT + low-calorie-diet background correctly flagged as not-STEP-1.
- STEP 5 (PMID 36216945): −15.2% vs −2.6% at 104 wk, 77.1% vs 34.4%, GI 82.2% vs 53.9% — identical. Treatment-regimen attribution confirmed: "Efficacy was assessed among all randomized participants regardless of …".
- SELECT (PMID 37952131): n=17,604, follow-up 39.8 mo, MACE 6.5% vs 8.0%, HR 0.80 (0.72–0.90, P<0.001), AE d/c 16.6% vs 8.2% — identical. No estimand swap; no rounded relative-risk headline.

**Absence claims — PASS (dated, windowed, re-verified).**
- TRIUMPH design (PMID 41090431): title topical-matches ("Rationale and design of the TRIUMPH registrational clinical trials", Diabetes Obes Metab 2026 Jan). Four Phase 3, >5,800 participants, primary weight end point = % body-weight change, no efficacy percent — confirmed.
- CT.gov v2 full records fetched by Judge: NCT05929066 COMPLETED 2335 ACTUAL hasResults:false · NCT05929079 COMPLETED 1152 ACTUAL hasResults:false · NCT05882045 COMPLETED 1946 ACTUAL hasResults:false · NCT05931367 COMPLETED 445 ACTUAL hasResults:false · NCT06383390 ACTIVE_NOT_RECRUITING 10000 ESTIMATED, completion 2029-02 ESTIMATED, hasResults:false. Page table matches all five rows exactly; absence dated 2026-09-02 with named search.
- openFDA: retatrutide drugsfda → HTTP 404 (page: "no match … accessed 2026-09-02"). NDA 209637 → brand_name OZEMPIC (page's Development Status table).

**False links — PASS.** Both internal hrefs resolve to real collection files (Test-Path True ×2). No `.mdx` URLs, no trailing slashes, no free-text slug links introduced.

**Identifier provenance — PASS.** Every source in frontmatter carries `verifiedAt: '2026-09-02'`; all were re-fetched by this Judge today and topical-match. No identifier beyond the implementer's fetched set.

## Gaming check

The increment was stripped, not papered over: the invented nausea-range table, fat-mass/liver-fat/A1C rows, census FAQ numbers, "~24%" hedge, and SELECT 20% headline are gone rather than reworded, and the "Metabolic measures not quoted" section discloses the removal instead of smuggling the numbers back (searched for 43/40, 67/52, 28.7, 63%/6% OSA, SYNCHRONY, amycretin ~13%/~25% — zero hits). The retained disavowal sentences ("does not quote a live source census", "does not invent a matched nausea-percent table") are meta-commentary addressed at auditors rather than readers — mildly odd copy, but true, and they do not reintroduce any stripped figure. Numbers were not rounded into safer-looking forms (−24.2% kept with its secondary label; SELECT kept as HR with event rates). The implementer explicitly declined to self-stamp KEEP, stayed off locked TICK19–30 files and `src/content/peptides/**`, and did not touch TICK6-PRICE. No graph/template changes to game. Absence claims were re-run by this Judge against live APIs today with identical results — the page's 2026-09-02 dates are honest.

## Observations (LOW — not blocking; fix on next touch)

- **LOW-1.** FAQ line 28 retains "This page does not quote a live source census." Reader-facing disavowal of a removed feature is dead copy; rewrite plainly or drop.
- **LOW-2.** FAQ "Can Retatrutide and Semaglutide be used together?" answers "There is no published clinical data…" — an undated universal absence. Low risk (no such trial plausibly exists) and not window-scoped, but it should carry a date or source per the absence-claim rule.

## Verdict

**KEEP.** All eight must-fail conditions pass; every quoted number re-verified against PubMed/CT.gov/openFDA fetches executed by this Judge on 2026-09-02; estimands correctly labeled; absences dated; links resolve; no self-KEEP. Two LOW copy notes for the next editor.
